Limits...
Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.

Bozzola M, Colle M, Halldin-Stenlid M, Larroque S, Zignani M, easypod™ survey study gro - BMC Endocr Disord (2011)

Bottom Line: Adherence was compared between GH treatment-naïve and treatment-experienced children.In children who received treatment with r-hGH using easypod™, short-term adherence is good, and significantly higher in treatment-naïve children compared with experienced children.Children/parents rate the device highly.

View Article: PubMed Central - HTML - PubMed

Affiliation: Paediatric Department, University of Pavia, IRCCS San Matteo Foundation, Pavia, Italy. mauro.bozzola@unipv.it.

ABSTRACT

Background: Accurately monitoring adherence to treatment with recombinant human growth hormone (r-hGH) enables appropriate intervention in cases of poor adherence. The electronic r-hGH auto-injector, easypod™, automatically records the patient's adherence to treatment. This study evaluated adherence to treatment of children who started using the auto-injector and assessed opinions about the device.

Methods: A multicentre, multinational, observational 3-month survey in which children received r-hGH as part of their normal care. Physicians reviewed the recorded dose history and children (with or without parental assistance) completed a questionnaire-based survey. Children missing ≤2 injections per month (92% of injections given) were considered adherent to treatment. Adherence was compared between GH treatment-naïve and treatment-experienced children.

Results: Of 834 recruited participants, 824 were evaluated. The median (range) age was 11 (1-18) years. From the recorded dose history, 87.5% of children were adherent to treatment over the 3-month period. Recorded adherence was higher in treatment-naïve (89.7%, n = 445/496) than in treatment-experienced children (81.7%, n = 152/186) [Fisher's exact test FI(X) = 7.577; p = 0.0062]. According to self-reported data, 90.2% (607/673) of children were adherent over 3 months; 51.5% (421/817) missed ≥1 injection over this period (mainly due to forgetfulness). Concordance between reported and recorded adherence was 84.3%, with a trend towards self-reported adherence being higher than recorded adherence. Most children liked the auto-injector: over 80% gave the top two responses from five options for ease of use (720/779), speed (684/805) and comfort (716/804). Although 38.5% (300/780) of children reported pain on injection, over half of children (210/363) considered the pain to be less or much less than expected. Given the choice, 91.8% (732/797) of children/parents would continue using the device.

Conclusions: easypod™ provides an accurate method of monitoring adherence to treatment with r-hGH. In children who received treatment with r-hGH using easypod™, short-term adherence is good, and significantly higher in treatment-naïve children compared with experienced children. Children/parents rate the device highly. The high level of acceptability of the device is reflected by a desire to continue using it by over 90% of the children in the survey.

No MeSH data available.


Related in: MedlinePlus

Geographic distribution of survey participants in the evaluable population.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3045978&req=5

Figure 1: Geographic distribution of survey participants in the evaluable population.

Mentions: The 824 children were recruited from 206 centres across 15 countries. The number of children recruited from each country is shown in Figure 1. Characteristics of the survey population are shown in Table 2. Parents administered the injections for 52.8% (430/815) of children. The median (range) age of children administering their own injections was 13 (5-18) years and for children whose parents took control of injections was 9 (1-18) years. Most children (564/798; 70.7%) were prescribed seven injections per week, with the remaining children prescribed only six injections per week.


Treatment adherence with the easypod™ growth hormone electronic auto-injector and patient acceptance: survey results from 824 children and their parents.

Bozzola M, Colle M, Halldin-Stenlid M, Larroque S, Zignani M, easypod™ survey study gro - BMC Endocr Disord (2011)

Geographic distribution of survey participants in the evaluable population.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3045978&req=5

Figure 1: Geographic distribution of survey participants in the evaluable population.
Mentions: The 824 children were recruited from 206 centres across 15 countries. The number of children recruited from each country is shown in Figure 1. Characteristics of the survey population are shown in Table 2. Parents administered the injections for 52.8% (430/815) of children. The median (range) age of children administering their own injections was 13 (5-18) years and for children whose parents took control of injections was 9 (1-18) years. Most children (564/798; 70.7%) were prescribed seven injections per week, with the remaining children prescribed only six injections per week.

Bottom Line: Adherence was compared between GH treatment-naïve and treatment-experienced children.In children who received treatment with r-hGH using easypod™, short-term adherence is good, and significantly higher in treatment-naïve children compared with experienced children.Children/parents rate the device highly.

View Article: PubMed Central - HTML - PubMed

Affiliation: Paediatric Department, University of Pavia, IRCCS San Matteo Foundation, Pavia, Italy. mauro.bozzola@unipv.it.

ABSTRACT

Background: Accurately monitoring adherence to treatment with recombinant human growth hormone (r-hGH) enables appropriate intervention in cases of poor adherence. The electronic r-hGH auto-injector, easypod™, automatically records the patient's adherence to treatment. This study evaluated adherence to treatment of children who started using the auto-injector and assessed opinions about the device.

Methods: A multicentre, multinational, observational 3-month survey in which children received r-hGH as part of their normal care. Physicians reviewed the recorded dose history and children (with or without parental assistance) completed a questionnaire-based survey. Children missing ≤2 injections per month (92% of injections given) were considered adherent to treatment. Adherence was compared between GH treatment-naïve and treatment-experienced children.

Results: Of 834 recruited participants, 824 were evaluated. The median (range) age was 11 (1-18) years. From the recorded dose history, 87.5% of children were adherent to treatment over the 3-month period. Recorded adherence was higher in treatment-naïve (89.7%, n = 445/496) than in treatment-experienced children (81.7%, n = 152/186) [Fisher's exact test FI(X) = 7.577; p = 0.0062]. According to self-reported data, 90.2% (607/673) of children were adherent over 3 months; 51.5% (421/817) missed ≥1 injection over this period (mainly due to forgetfulness). Concordance between reported and recorded adherence was 84.3%, with a trend towards self-reported adherence being higher than recorded adherence. Most children liked the auto-injector: over 80% gave the top two responses from five options for ease of use (720/779), speed (684/805) and comfort (716/804). Although 38.5% (300/780) of children reported pain on injection, over half of children (210/363) considered the pain to be less or much less than expected. Given the choice, 91.8% (732/797) of children/parents would continue using the device.

Conclusions: easypod™ provides an accurate method of monitoring adherence to treatment with r-hGH. In children who received treatment with r-hGH using easypod™, short-term adherence is good, and significantly higher in treatment-naïve children compared with experienced children. Children/parents rate the device highly. The high level of acceptability of the device is reflected by a desire to continue using it by over 90% of the children in the survey.

No MeSH data available.


Related in: MedlinePlus